Cytosorbents (CTSO) Stock Price
Cytosorbents Price
Revenue has compounded at 64.1% per year over the past 14 years to 37.06 M USD. Cytosorbents's net margin stands at -22.1%, up from -61.2% several years earlier. Analysts set a median price target of 5.10 USD, implying 24.1% above the current price. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus.
Cytosorbents stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cytosorbents business model & stock analysis
Frequently asked questions about Cytosorbents
The business model of Cytosorbents Corp involves the development and commercialization of technologies for blood purification. The company specializes in the production of devices that are designed to remove harmful substances from the bloodstream, including toxins, cytokines, and pathogens. This process is aimed at improving patient outcomes in various medical conditions, such as sepsis, cytokine storm, and other critical illnesses. Cytosorbents Corp's innovative products, like the CytoSorb® Therapy, offer healthcare professionals a versatile tool to help reduce inflammation and manage complications associated with excessive immune response. Overall, the company focuses on advancing blood purification technologies to enhance patient care and address unmet medical needs efficiently.
Cytosorbents Corp is primarily active in the medical device industry.
The main competitors of Cytosorbents Corp in the market include companies such as Baxter International Inc., Medtronic plc, and Terumo Corporation. These companies also operate in the medical device industry and offer products and solutions similar to Cytosorbents Corp's blood purification technology. Cytosorbents Corp distinguishes itself through its innovative CytoSorb® therapy, which efficiently removes toxins and cytokines from the bloodstream, providing better patient outcomes. Despite the competitive landscape, Cytosorbents Corp continues to stand out as a leader in the field with its unique and effective medical technology.
Cytosorbents Corp is a renowned biotechnology company specializing in blood purification. Founded in 1997, the company has steadily evolved into a global leader in critical care immunotherapy. Cytosorbents Corp focuses on developing and commercializing proprietary products, such as the CytoSorb therapy, which uses its innovative blood purification technology to treat severe inflammation, sepsis, and other life-threatening conditions. With a passion for improving patient outcomes, Cytosorbents Corp has formed strategic partnerships and gained regulatory approvals worldwide. The company's commitment to innovation and its dedication to addressing unmet medical needs position Cytosorbents Corp as a significant player in the biotechnology industry.
Cytosorbents Corp has achieved several significant milestones. The company successfully obtained FDA approval for its flagship product, CytoSorb, which is a blood purification technology used to treat critically-ill patients. It has also received regulatory clearances in various countries, expanding its global presence. Cytosorbents Corp has partnered with renowned medical institutions and established strategic collaborations with industry leaders. The company continually invests in research and development, leading to multiple patents and groundbreaking innovations. With its persistent dedication, Cytosorbents Corp has revolutionized the field of blood purification, improving patient outcomes and solidifying its position as a leader in the industry.
Cytosorbents Corp is primarily present in multiple countries and regions worldwide. The company is based in the United States (US) and has a significant presence across North America. It has also expanded its operations and established a strong presence in Europe, particularly in countries like Germany, France, and Italy. Additionally, Cytosorbents Corp operates in Asia, with a focus on countries such as Japan and China. The company's global presence allows it to serve a wide range of markets and provide its innovative medical technologies and products internationally.
Cytosorbents Corp represents a commitment to improving patient outcomes through innovative medical technology. The company's core values include dedication to clinical excellence, patient-centric care, and continuous innovation. Cytosorbents Corp's corporate philosophy revolves around providing advanced therapies and solutions to treat life-threatening conditions, such as sepsis and organ failure. With a focus on research and development, the company strives to develop and commercialize cutting-edge medical devices that can revolutionize the field of healthcare. Through its efforts, Cytosorbents Corp aims to make a significant impact on patient care and contribute to the advancement of medical science.
Analysts currently set an average price target of 5.36 USD for the Cytosorbents stock (median: 5.10 USD), implying +30.3 % versus the latest price. The consensus is based on 8 analyst ratings.
6 analysts currently rate the Cytosorbents stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect Cytosorbents to generate revenue of 38.88 M USD and earnings per share of -3.81 USD.
Converted at the current exchange rate, the Cytosorbents share trades at 3.66 EUR (4.11 USD).
The Cytosorbents share (CTSO) is listed on 5 stock exchanges, including: NASDAQ (CTSO), SIX (Zürich) (HQE1.SW), Frankfurt (HQE1.F), München (HQE1.MU), Düsseldorf (HQE1.DU).
Cytosorbents Corp is a company specializing in the development and distribution of products for blood detoxification. Its business model is based on three pillars: product sales, licensing of technologies, and collaboration with partners. The company's main product line is Cytosorb, an extracorporeal system for the removal of toxins and inflammatory mediators from the blood. It sells its products mainly to hospitals and medical facilities worldwide. The company also focuses on product and technology development, working closely with medical and research institutions to explore new applications of Cytosorb. It has a strong patent portfolio and strategic partnerships with companies such as Fresenius Medical Care, Medtronic, and Oxiris. The company has also expanded into the veterinary medicine market through its subsidiary Vetco. It has experienced strong growth in recent years, with double-digit revenue increases and improved profit margins. The company is optimistic about the future and believes that the demand for its products will continue to grow, supported by new applications, expansion into the veterinary medicine market, and its strong patent position.
The expected revenue of Cytosorbents is 38.88 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Cytosorbents is -11.98 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Cytosorbents is currently -1.08. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cytosorbents stock.
The price-to-sales ratio (P/S) of Cytosorbents is currently 0.33. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cytosorbents stock.
The Eulerpool Quality Score for Cytosorbents is 3/10.
The ISIN of Cytosorbents is US23283X2062. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Cytosorbents is A12GDU. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Cytosorbents is CTSO. The ticker symbol is used to trade Cytosorbents shares on the stock exchange.
Cytosorbents stock
Cytosorbents Peer Group
Cytosorbents Ticker
Cytosorbents FIGI
All fundamentals and in-depth analysis of Cytosorbents
Our stock analysis for Cytosorbents stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cytosorbents. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.